马拉维卡介苗复种:大型随机双盲安慰剂对照试验30年随访
BACKGROUND: A large, double-blind, randomised, placebo-controlled trial of repeat BCG found 49% efficacy against leprosy but no protection against tuberculosis after 6-9 years' follow-up in 1995.…
要点
- 复种对麻风保护在接种10年后无证据。
核心结论
- 在HIV高流行的非洲农村人群中,复种卡介苗对总体结核无显著保护。
- HIV阴性结核及儿童期接种者亚组可见 modest 保护,但多重分析下不宜过度解读。
研究设计与样本
- 随访至2018年底,采用增强被动监测,结核病例定义包括严格的微生物学或组织学确认。
主要发现
- 随访期间824例发生结核,其中786例为肺结核,607例已知HIV状态者中383例(63%)HIV阳性。
- 接种时结核菌素状态及菌株谱系间无差异;接种10年后无麻风保护证据(1995年后仅9例诊断明确)。
临床怎么用
- 不支持在HIV高流行农村人群中以复种卡介苗作为结核控制策略。
- 对HIV阴性结核及儿童期接种者的亚组保护信号需结合其他证据谨慎解读。
局限性
- 亚组效应基于多重分析,不宜过度解读。
- 麻风保护评估受限于1995年后诊断明确病例极少(仅9例)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: A large, double-blind, randomised, placebo-controlled trial of repeat BCG found 49% efficacy against leprosy but no protection against tuberculosis after 6-9 years' follow-up in 1995. We report here additional follow-up, which resulted in greatly increased tuberculosis case numbers, and allowed subgroup analysis. METHODS: Nearly 47 000 individuals of all ages living in northern Malawi with a BCG vaccine scar were randomly assigned (1:1) between 1986 and 1989 to receive a second BCG or placebo. The investigators and project staff remained masked to all interventions. Enhanced passive surveillance ensured ascertainment of tuberculosis and leprosy to the end of 2018. Tuberculosis case definitions included rigorous microbiological or histological confirmation. Prespecified subgroup analyses were by tuberculosis type, age at vaccination, time since vaccination, previous tuberculin reactivity, HIV status and Mycobacterium tuberculosis lineage. The original trial is registered with ISRCTN registry, ISRCTN11311670. FINDINGS: In follow-up until Dec 31, 2018, 824 participants had developed tuberculosis, including 786 with pulmonary disease, of whom 383 (63%) of 607 with known HIV status were HIV positive. There was no effect of a second BCG overall (odds ratio [OR] 0·92; 95% CI 0·80-1·05), or for pulmonary (0·93; 0·81-1·07), or lymph node tuberculosis (0·60; 0·31-1·17). The OR was lower for those with known HIV-negative tuberculosis (0·77; 0·59-1·00), for those vaccinated as children (aged <5 years, 0·74; 0·41-1·35; aged 5-14 years, 0·77; 0·60-0·99), and for cases arising at least 20 years after vaccination (0·79; 0·63-1·01). There were no differences by tuberculin status at vaccination, or lineage. There was no evidence of protection against leprosy beyond 10 years after vaccination (although there have been only nine diagnostically certain cases since 1995). INTERPRETATION: There was no evidence that repeat BCG vaccination provides appreciable protection against overall tuberculosis in this rural African population with a high prevalence of HIV. Subgroup effects should not be overinterpreted given the multiple analyses done. However, the evidence for modest protection against HIV-negative tuberculosis, and for a delayed benefit in those vaccinated as children, is consistent with other observations in the literature. FUNDING: LEPRA, Wellcome Trust, Bill & Melinda Gates Foundation.
引用
- Glynn JR, Fielding K, Mzembe T, et al. BCG re-vaccination in Malawi: 30-year follow-up of a large, randomised, double-blind, placebo-controlled trial. Lancet Glob Health. 2021. PMID: 34534489. doi:10.1016/S2214-109X(21)00309-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。